Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-08-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the use of part of idle raised funds for cash management. It details the amount of funds raised through convertible bonds, the investment projects, the current status of fund usage, and the company's plan to invest idle funds in low-risk financial products. The document includes information about board and supervisory committee approvals and the sponsor's verification. It is a regulatory announcement about the company's financing fund usage and cash management, not a financial report or audit. The document length is 4438 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial statement or comprehensive financial analysis. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement about fund usage and cash management.
2025-08-28 Chinese
奥锐特药业股份有限公司董事、高级管理人员离职管理制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled '董事、高级管理人员离职管理制度' which translates to 'Board and Senior Management Resignation Management System'. It outlines the procedures, principles, responsibilities, and obligations related to the resignation or departure of company directors and senior management personnel. The content is focused on governance policies and internal rules regarding management changes rather than announcing specific personnel changes or financial results. It is not a report of actual changes (which would be MANG), nor is it a proxy statement, voting result, or regulatory filing about a specific event. It is a governance document detailing internal rules and procedures for management departures, fitting the Governance Information (CGR) category. The document length is 3036 characters, which is substantive and contains detailed governance policies, not a brief announcement or certification. Therefore, the classification is Governance Information (CGR) with high confidence.
2025-08-28 Chinese
奥锐特药业股份有限公司会计师事务所选聘制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '会计师事务所选聘制度' (Accounting Firm Selection System) issued by 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.). It outlines procedures, requirements, and governance related to the selection, appointment, and replacement of the company's external auditors (accounting firms). It includes governance rules, evaluation criteria, and supervisory responsibilities but does not contain any financial statements, audit opinions, or audit reports themselves. It is not an audit report or annual report but rather a governance or procedural document related to audit firm selection. This fits best under Governance Information (CGR), which covers internal rules and governance practices. The document is about internal governance procedures for auditor selection, not an announcement or a report publication. The length is 4459 characters, which is substantive and not a brief announcement. Therefore, the classification is CGR with high confidence.
2025-08-28 Chinese
奥锐特药业股份有限公司对外担保制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is a detailed internal control policy regarding the company's external guarantee system, including procedures, risk management, approval processes, and responsibilities. It references relevant laws and regulations but does not contain financial statements, earnings data, or shareholder meeting results. It is a governance-related document outlining company rules and internal controls rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length (5508 characters) and content confirm it is not a brief announcement or certification but a substantive governance policy document.
2025-08-28 Chinese
奥锐特药业股份有限公司独立董事工作细则（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled '独立董事工作细则' which translates to 'Independent Director Work Rules' or 'Independent Director Working Guidelines'. It details the roles, responsibilities, qualifications, nomination, election, and working conditions of independent directors in the company. It references relevant laws, regulations, and company bylaws. The content is governance-related, focusing on internal rules and practices for board members, specifically independent directors. There is no financial data, no audit information, no earnings or capital updates, no voting results, no legal proceedings, and no mention of report publication or announcements. The document is a detailed governance framework document, fitting the category of Governance Information (CGR). The document length is 6617 characters, which is substantive and not a mere announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2025-08-28 Chinese
奥锐特药业股份有限公司股东会议事规则（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled '股东会议事规则' which translates to 'Rules of Procedure for Shareholders' Meetings' of 奥锐特药业股份有限公司. It details the procedures, powers, and regulations governing the company's shareholders meetings, including the convening, proposal submission, voting, and record-keeping processes. It does not contain financial statements, audit results, or earnings data. It is a governance document outlining internal rules and practices related to shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length (8511 characters) and content confirm it is a full governance rules document, not a brief announcement or a report publication notice.
2025-08-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.